



## Rallybio to Present at the 2022 Wells Fargo Healthcare Conference

August 31, 2022 at 8:00 AM EDT

NEW HAVEN, Conn.--(BUSINESS WIRE)--Aug. 31, 2022-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that company management will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 3:10 p.m. ET in Everett, MA.

A live webcast of the fireside chat will be accessible through the [Events and Presentations](#) section of Rallybio's website at [www.rallybio.com](http://www.rallybio.com). An archived replay of the webcast will be available for 30 days following the presentation.

### About Rallybio

Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company's mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut's Technology Incubation Program in Farmington, Connecticut. For more information, please visit [www.rallybio.com](http://www.rallybio.com).



View source version on [businesswire.com](https://www.businesswire.com/news/home/20220830005665/en/): <https://www.businesswire.com/news/home/20220830005665/en/>

### Investor Contacts

Steven Tuch  
Head of Corporate Development  
415-218-0697  
[stuch@rallybio.com](mailto:stuch@rallybio.com)

Ami Bavishi  
Head of Investor Relations and Communications  
475-47-RALLY (Ext. 282)  
[abavishi@rallybio.com](mailto:abavishi@rallybio.com)

Hannah Deresiewicz  
Stern Investor Relations, Inc.  
212-362-1200  
[hannah.deresiewicz@sternir.com](mailto:hannah.deresiewicz@sternir.com)

### Media Contact

Tara DiMilia  
908-369-7168  
[Tara.dimilia@tmstrat.com](mailto:Tara.dimilia@tmstrat.com)

Source: Rallybio Corporation